Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,207 Cr
Revenue (TTM)
₹594 Cr
Net Profit (TTM)
₹249 Cr
ROE
24.7 %
ROCE
24.2 %
P/E Ratio
4.9
P/B Ratio
0.9
Industry P/E
33.74
EV/EBITDA
12.8
Div. Yield
0 %
Debt to Equity
0
Book Value
₹158.8
EPS
₹6.3
Face value
10
Shares outstanding
86,836,558
CFO
₹600.18 Cr
EBITDA
₹1,459.36 Cr
Net Profit
₹646.43 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| 57.5 | -4.5 | 53.4 | 52.9 | 36.0 | 13.1 | 11.6 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
| -19.9 | 1.7 | 49.1 | 2.2 | 4.0 | 160.5 | -51.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ind-Swift Lab
|
138.9 | 1,207.0 | 594.5 | 248.5 | -5.0 | 3.5 | 4.9 | 0.9 |
| 352.7 | 3,213.2 | 2,521.8 | 202.5 | 9.6 | 14.3 | 15.9 | 2.1 | |
| 989.6 | 12,119.0 | 2,512.3 | 543.7 | 28.3 | 19.3 | 22.3 | 3.8 | |
| 357.4 | 6,190.1 | 1,053.1 | 293.6 | 32.3 | 24.6 | 21.1 | 4.8 | |
| 1,025.1 | 10,733.1 | 1,158.7 | 309.6 | 31.9 | 17.3 | 34.3 | 5.7 | |
| 1,547.6 | 29,354.2 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 12,433.0 | 15,953.0 | 1,575.1 | 179.1 | 14.9 | 11.4 | 89.1 | 9.6 | |
| 1,921.2 | 3,180.4 | 673.7 | 202.6 | 17.6 | 19.4 | 15.7 | 5.5 | |
| 784.3 | 3,617.1 | 588.5 | 102.9 | 22.1 | 12.7 | 35.6 | 4.3 | |
| 158.0 | 4,151.0 | 7.1 | -274.7 | -4,008.3 | -140.4 | -- | 6.2 |
Pledging Gamble Sours for these Companies
2 min read•By Vikas Vardhan
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic... areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, alcohol abstinence, antineoplastic, ADHD symptoms, anticancer, hypercholesterolemia, antimuscarinic, antimigraine, and thrombocytopenia. It also provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, azithromycin dihydrate, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, clopidogrel hydrochloride, dapoxetine hydrochloride, donepezil hydrochloride, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nateglinide, nitazoxanide, nitrosamine, pazopanib hydrochloride, quetiapine hemifumarate, raltegravir potassium, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide, as well as contract research and manufacturing services. The company exports its products. Ind-Swift Laboratories Limited was incorporated in 1995 and is based in Manimajra, India. Read more
Incorporated
1995
Chairman
Navrattan Munjal
Managing Director
Navrattan Munjal
Headquarters
Chandigarh, Union Territory
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ind-Swift Laboratories Ltd is ₹138.85 (NSE) and ₹139.00 (BSE) as of 02-Apr-2026 IST. Ind-Swift Laboratories Ltd has given a return of 36% in the last 3 years.
The P/E ratio of Ind-Swift Laboratories Ltd is 4.86 times as on 02-Apr-2026, a 86 discount to its peers’ median range of 33.74 times.
The P/B ratio of Ind-Swift Laboratories Ltd is 0.88 times as on 02-Apr-2026, a 59 discount to its peers’ median range of 2.13 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
2.30
|
0.53
|
|
2024
|
1.38
|
0.62
|
|
2023
|
6.86
|
0.66
|
|
2022
|
0.00
|
0.97
|
|
2021
|
0.00
|
1.09
|
The 52-week high and low of Ind-Swift Laboratories Ltd are Rs 151.98 and Rs 68.72 as of 03-Apr-2026.
Ind-Swift Laboratories Ltd has a market capitalisation of ₹ 1,207 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ind-Swift Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.68
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.